Cargando…
Experience with procalcitonin use during the COVID-19 pandemic
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008189/ https://www.ncbi.nlm.nih.gov/pubmed/35465971 http://dx.doi.org/10.1016/j.ejim.2022.04.002 |
_version_ | 1784686994261016576 |
---|---|
author | Gonzalez, Laura Holman, Thomas Wait, Daniel Abenojar, Pearl |
author_facet | Gonzalez, Laura Holman, Thomas Wait, Daniel Abenojar, Pearl |
author_sort | Gonzalez, Laura |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9008189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90081892022-04-14 Experience with procalcitonin use during the COVID-19 pandemic Gonzalez, Laura Holman, Thomas Wait, Daniel Abenojar, Pearl Eur J Intern Med Letter to the Editor Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. 2022-08 2022-04-14 /pmc/articles/PMC9008189/ /pubmed/35465971 http://dx.doi.org/10.1016/j.ejim.2022.04.002 Text en Crown Copyright © 2022 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to the Editor Gonzalez, Laura Holman, Thomas Wait, Daniel Abenojar, Pearl Experience with procalcitonin use during the COVID-19 pandemic |
title | Experience with procalcitonin use during the COVID-19 pandemic |
title_full | Experience with procalcitonin use during the COVID-19 pandemic |
title_fullStr | Experience with procalcitonin use during the COVID-19 pandemic |
title_full_unstemmed | Experience with procalcitonin use during the COVID-19 pandemic |
title_short | Experience with procalcitonin use during the COVID-19 pandemic |
title_sort | experience with procalcitonin use during the covid-19 pandemic |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008189/ https://www.ncbi.nlm.nih.gov/pubmed/35465971 http://dx.doi.org/10.1016/j.ejim.2022.04.002 |
work_keys_str_mv | AT gonzalezlaura experiencewithprocalcitoninuseduringthecovid19pandemic AT holmanthomas experiencewithprocalcitoninuseduringthecovid19pandemic AT waitdaniel experiencewithprocalcitoninuseduringthecovid19pandemic AT abenojarpearl experiencewithprocalcitoninuseduringthecovid19pandemic |